|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2004-11-16
|
|
pubmed:abstractText |
The first antagonists known for the histamine H3 receptor were mono-substituted imidazole-containing compounds like thioperamide. Meanwhile numerous novel leads have been developed possessing improved affinities, selectivities, specificities, and pharmacokinetic properties. Scope and limitations of this promising class are discussed concerning their structure-activity relationships as well as pharmacological and potential therapeutic aspects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1389-5575
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
4
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
965-77
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Medicinal chemical and pharmacological aspects of imidazole-containing histamine H3 receptor antagonists.
|
|
pubmed:affiliation |
Johann Wolfgang Goethe-Universität, Institut für Pharmazeutische Chemie, Biozentrum, Marie-Curie-Strasse 9, 60439 Frankfurt am Main, Germany. h.stark@pharmchem.uni-frankfurt.de.
|
|
pubmed:publicationType |
Journal Article,
Review
|
